{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:27:14Z","timestamp":1782307634166,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03203-1","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T19:03:21Z","timestamp":1762196601000},"page":"786-799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical, genetic, and nutritional determinants of INR: role of plasma warfarin and hydroxylated metabolite levels in anticoagulated Mexican patients"],"prefix":"10.1007","volume":"59","author":[{"given":"Omar","family":"Rodr\u00edguez-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"L\u00f3pez-Quijano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Jazm\u00edn","family":"Rodr\u00edguez-Pinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Vargas-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-3745","authenticated-orcid":false,"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-8184","authenticated-orcid":false,"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Augusto","family":"Gordillo-Moscoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4906-223X","authenticated-orcid":false,"given":"\u00darsula Fabiola","family":"Medina-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-8474","authenticated-orcid":false,"given":"Susanna Edith","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"3203_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41397-019-0083-3","volume":"19","author":"X Li","year":"2019","unstructured":"Li X, Li D, Wu JC, Liu ZQ, Zhou HH, Yin JY (2019) Precision dosing of warfarin: open questions and strategies. Pharmacogenomics J 19:219\u2013229. https:\/\/doi.org\/10.1038\/s41397-019-0083-3","journal-title":"Pharmacogenomics J"},{"key":"3203_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15446\/revfacmed.v64n2.49963","volume":"64","author":"RG Jaramillo-Salamanca","year":"2016","unstructured":"Jaramillo-Salamanca RG, Jim\u00e9nez-G\u00f3mez JD, Pinilla-Roa AE (2016) Use of direct oral anticoagulants in clinical practice. Rev Fac Med 64:295\u2013308. https:\/\/doi.org\/10.15446\/revfacmed.v64n2.49963","journal-title":"Rev Fac Med"},{"key":"3203_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.recesp.2011.03.015","volume":"64","author":"JC Kaski","year":"2011","unstructured":"Kaski JC, Arrebola-Moreno AL (2011) Inflammation and thrombosis in atrial fibrillation. Rev Esp Cardiol 64:551\u2013553. https:\/\/doi.org\/10.1016\/j.recesp.2011.03.015","journal-title":"Rev Esp Cardiol"},{"key":"3203_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/MEDSCI10020032","volume":"10","author":"JS Aluru","year":"2022","unstructured":"Aluru JS, Barsouk A, Saginala K, Rawla P, Barsouk A (2022) Valvular Heart Disease Epidemiol Med Sci 10:32. https:\/\/doi.org\/10.3390\/MEDSCI10020032","journal-title":"Valvular Heart Disease Epidemiol Med Sci"},{"key":"3203_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al (2013) Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369:1206\u20131220. https:\/\/doi.org\/10.1056\/NEJMoa1300615","journal-title":"N Engl J Med"},{"key":"3203_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11096-021-01309-z","volume":"44","author":"YL Huang","year":"2022","unstructured":"Huang YL, Chen CY, Chu CC (2022) Risk of major bleeding and thromboembolism in Asian patients with nonvalvular atrial fibrillation using direct oral anticoagulants versus warfarin. Int J Clin Pharm 44:34\u201343. https:\/\/doi.org\/10.1007\/s11096-021-01309-z","journal-title":"Int J Clin Pharm"},{"key":"3203_CR7","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00210-020-02037-3","volume":"394","author":"X Ning","year":"2021","unstructured":"Ning X, Kuang Y, Yang G, Xie J, Miao D, Guo C et al (2021) Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. Naunyn Schmiedebergs Arch Pharmacol 394:1275\u20131283. https:\/\/doi.org\/10.1007\/s00210-020-02037-3","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3203_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7197\/cmj.1415665","volume":"46","author":"Z Keskin","year":"2024","unstructured":"Keskin Z, Gedikli MA (2024) Determination of the percentage of patients using warfarin to reach target INR. Cumhur Med J 46:41\u201344. https:\/\/doi.org\/10.7197\/cmj.1415665","journal-title":"Cumhur Med J"},{"key":"3203_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.20517\/JCA.2023.33","volume":"3","author":"R Morris","year":"2023","unstructured":"Morris R, Todd M, Aponte NZ, Salcedo M, Bruckner M, Garcia AS et al (2023) The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS). J Cardiovasc Aging 3:39. https:\/\/doi.org\/10.20517\/JCA.2023.33","journal-title":"J Cardiovasc Aging"},{"key":"3203_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01065653","volume":"13","author":"DR Mungall","year":"1985","unstructured":"Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH (1985) Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 13:213\u2013227. https:\/\/doi.org\/10.1007\/BF01065653","journal-title":"J Pharmacokinet Biopharm"},{"key":"3203_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00003088-198611060-00005","volume":"11","author":"NHG Holford","year":"1986","unstructured":"Holford NHG (1986) Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 11:483\u2013504. https:\/\/doi.org\/10.2165\/00003088-198611060-00005","journal-title":"Clin Pharmacokinet"},{"key":"3203_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/cpt1974154424","volume":"15","author":"A Breckenridge","year":"1974","unstructured":"Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424\u2013430. https:\/\/doi.org\/10.1002\/cpt1974154424","journal-title":"Clin Pharmacol Ther"},{"key":"3203_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5377\/torreon.v10i27.10842","volume":"10","author":"S Negaresh","year":"2021","unstructured":"Negaresh S, Silva Arrechavala JR, Corriols M (2021) Polimorfismos gen\u00e9ticos CYP2C9 y VKORC1-1639 implicados En La farmacocin\u00e9tica y farmacodin\u00e1mica de warfarina En poblaci\u00f3n Latinoamericana. Revista Torre\u00f3n Universitario 10:76\u201391. https:\/\/doi.org\/10.5377\/torreon.v10i27.10842","journal-title":"Revista Torre\u00f3n Universitario"},{"key":"3203_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jchromb.2004.12.024","volume":"818","author":"I Locatelli","year":"2005","unstructured":"Locatelli I, Kmetec V, Mrhar A, Grabnar I (2005) Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818:191\u2013198. https:\/\/doi.org\/10.1016\/j.jchromb.2004.12.024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3203_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jpba.2010.01.005","volume":"52","author":"Z Zuo","year":"2010","unstructured":"Zuo Z, Wo SK, Lo CMY, Zhou L, Cheng G, You JHS (2010) Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 52:305\u2013310. https:\/\/doi.org\/10.1016\/j.jpba.2010.01.005","journal-title":"J Pharm Biomed Anal"},{"key":"3203_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0162084","volume":"11","author":"D Gemmati","year":"2016","unstructured":"Gemmati D, Burini F, Talarico A, Fabbri M, Bertocco C, Vigliano M et al (2016) The active metabolite of warfarin (3\u2032-hydroxywarfarin) and correlation with INR, warfarin and drug weekly dosage in patients under oral anticoagulant therapy: A pharmacogenetics study. PLoS ONE 11:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0162084","journal-title":"PLoS ONE"},{"key":"3203_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jyp.2013.02.001","volume":"5","author":"DK Kumar","year":"2013","unstructured":"Kumar DK, Shewade DG, Parasuraman S, Rajan S, Balachander J, Chandran BVS et al (2013) Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy. J Young Pharm 5:13\u201317. https:\/\/doi.org\/10.1016\/j.jyp.2013.02.001","journal-title":"J Young Pharm"},{"key":"3203_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/clpt.2010.13","volume":"87","author":"P Lenzini","year":"2010","unstructured":"Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M et al (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87:572\u2013578. https:\/\/doi.org\/10.1038\/clpt.2010.13","journal-title":"Clin Pharmacol Ther"},{"key":"3203_CR19","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/CIR.0000000000001193\/FORMAT\/EPUB","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM et al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. Circulation 149:E1\u2013156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193\/FORMAT\/EPUB","journal-title":"Circulation"},{"key":"3203_CR20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11096-022-01386-8","volume":"44","author":"AM Fahmi","year":"2022","unstructured":"Fahmi AM, Elewa H, El Jilany I (2022) Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Int J Clin Pharm 44:599\u2013607. https:\/\/doi.org\/10.1007\/s11096-022-01386-8","journal-title":"Int J Clin Pharm"},{"key":"3203_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jelectrocard.2012.11.002","volume":"46","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Daubert JP (2013) Dose-adjusted warfarin: writing the prescription is only the beginning. J Electrocardiol 46:51\u201353. https:\/\/doi.org\/10.1016\/j.jelectrocard.2012.11.002","journal-title":"J Electrocardiol"},{"key":"3203_CR22","first-page":"9","volume":"20","author":"C Tajer","year":"2016","unstructured":"Tajer C, Ceresetto J, Bottaro F, Mart\u00ed A, Casey M (2016) Evaluaci\u00f3n Del Tiempo En Rango terap\u00e9utico En Pacientes Con fibrilaci\u00f3n auricular tratados cr\u00f3nicamente Con antagonistas de La vitamina K Por especialistas En hemostasia de La Argentina. Registro TERRA (Tiempo En Rango En La Rep\u00fablica Argentina). Hematol 20:9\u201326","journal-title":"Hematol"},{"key":"3203_CR23","first-page":"42","volume":"41","author":"H Miranda","year":"2016","unstructured":"Miranda H, Os\u00f3rio S, Giraldo DP, Duque J, Ubeimar-Cata\u00f1o J, Tob\u00f3n LI et al (2016) Time in therapeutic range (TTR) in anticoagulation clinic. Reports of adverse events and factors associated with low TTR. Acta Med Colomb 41:42\u201348","journal-title":"Acta Med Colomb"},{"key":"3203_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7705\/biomedica.v30i3.275","volume":"30","author":"C Isaza","year":"2010","unstructured":"Isaza C, Beltr\u00e1n L, Henao J, Porras G, Pinz\u00f3n A, Vallejos A et al (2010) Factores gen\u00e9ticos y ambientales asociados Con La respuesta a warfarina En Pacientes Colombianos. Biomedica 30:410\u2013420","journal-title":"Biomedica"},{"key":"3203_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.FPC.0000114760.08559.DC","volume":"14","author":"MA Hillman","year":"2004","unstructured":"Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539\u2013547. https:\/\/doi.org\/10.1097\/01.FPC.0000114760.08559.DC","journal-title":"Pharmacogenetics"},{"key":"3203_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.tpj.6500308","volume":"5","author":"D Herman","year":"2005","unstructured":"Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A et al (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5:193\u2013202. https:\/\/doi.org\/10.1038\/sj.tpj.6500308","journal-title":"Pharmacogenomics J"},{"key":"3203_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMOA0809329","volume":"360","author":"T Klein","year":"2009","unstructured":"Klein T, Altman R, Eriksson N, Gage B, Kimmel S, Lee M et al (2009) Estimation of the warfarin dose with clinical and Pharmacogenetic data. N Engl J Med 360:753\u2013764. https:\/\/doi.org\/10.1056\/NEJMOA0809329","journal-title":"N Engl J Med"},{"key":"3203_CR28","unstructured":"U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations. (2018)"},{"key":"3203_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4067\/S0717-75182018000500363","volume":"45","author":"D Dias Mendon\u00e7a","year":"2018","unstructured":"Dias Mendon\u00e7a D, Zuchinali P, Souza GC (2018) Development of a food frequency questionnaire to determine vitamin K intake in anticoagulated patients: a pilot study. Rev Chil Nutr 45:363\u2013371. https:\/\/doi.org\/10.4067\/S0717-75182018000500363","journal-title":"Rev Chil Nutr"},{"key":"3203_CR30","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1182\/BLOOD-2005-03-1108","volume":"106","author":"EA Sconce","year":"2005","unstructured":"Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329\u20132333. https:\/\/doi.org\/10.1182\/BLOOD-2005-03-1108","journal-title":"Blood"},{"key":"3203_CR31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1373\/CLINCHEM.2006.078139","volume":"53","author":"Y Zhu","year":"2007","unstructured":"Zhu Y, Shennan M, Reynolds KK, Johnson NA, Herrnberger MR, Valdes R et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (\u2013\u20091639 G\u2009>\u2009A) and CYP2C9 genotypes. Clin Chem 53:1199\u20131205. https:\/\/doi.org\/10.1373\/CLINCHEM.2006.078139","journal-title":"Clin Chem"},{"key":"3203_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/clpt.2008.10","volume":"84","author":"B Gage","year":"2008","unstructured":"Gage B, Eby C, Johnson J, Deych E, Rieder M, Ridker P et al (2008) Use of Pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin NIH public access author manuscript. Clin Pharmacol Ther 84:326\u2013331. https:\/\/doi.org\/10.1038\/clpt.2008.10","journal-title":"Clin Pharmacol Ther"},{"key":"3203_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/BLOOD-2008-04-149070","volume":"113","author":"M Wadelius","year":"2009","unstructured":"Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784\u2013792. https:\/\/doi.org\/10.1182\/BLOOD-2008-04-149070","journal-title":"Blood"},{"key":"3203_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/S11239-010-0459-3","volume":"30","author":"PB Shaw","year":"2010","unstructured":"Shaw PB, Donovan JL, Tran MT, Lemon SC, Burgwinkle P, Gore J (2010) Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis 30:220\u2013225. https:\/\/doi.org\/10.1007\/S11239-010-0459-3","journal-title":"J Thromb Thrombolysis"},{"key":"3203_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.thromres.2009.07.006","volume":"125","author":"S Schulman","year":"2010","unstructured":"Schulman S, Melinyshyn A, Ennis D, Rudd-Scott L (2010) Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. Thromb Res 125:393\u2013397. https:\/\/doi.org\/10.1016\/j.thromres.2009.07.006","journal-title":"Thromb Res"},{"key":"3203_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11606-023-08348-4","volume":"39","author":"A Van Beek","year":"2024","unstructured":"Van Beek A, Moeyaert M, Ragheb B, Price E, MacEwan JP, Ahmed N et al (2024) Outcomes of warfarin home INR monitoring vs office-based monitoring: a retrospective claims-based analysis. J Gen Intern Med 39:1127\u20131134. https:\/\/doi.org\/10.1007\/s11606-023-08348-4","journal-title":"J Gen Intern Med"},{"key":"3203_CR37","first-page":"32","volume":"24","author":"FL Gonz\u00e1lez","year":"2020","unstructured":"Gonz\u00e1lez FL, Gonz\u00e1lez Silva NE, Ortelli Tomada GM, Sancassani PE, Mathieu ME (2020) Valoraci\u00f3n Del Tiempo En Rango terap\u00e9utico En Pacientes Bajo Tratamiento Con antagonistas orales de La vitamina K En Un Centro de anticoagulaci\u00f3n. Hematol 24:32\u201339","journal-title":"Hematol"},{"key":"3203_CR38","first-page":"311","volume":"29","author":"G\u00f3mez Andreina","year":"2014","unstructured":"Andreina G\u00f3mez, Stephania Peixoto, Mar\u00eda Azc\u00fanaga, Alejandra Gama, Natalia Lluberas, Pablo \u00c1lvarez (2014) Calidad de la anticoagulaci\u00f3n oral con warfarina en una policl\u00ednica de cardiolog\u00eda: porcentaje de tiempo en rango terap\u00e9utico. Rev Urug Cardiol 29:311\u2013316","journal-title":"Rev Urug Cardiol"},{"key":"3203_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3889\/OAMJMS.2020.3436","volume":"8","author":"R Rahmatini","year":"2020","unstructured":"Rahmatini R, Aliska G, Usman E, Yanni M, Ilmiawati C (2020) Plasma warfarin level and international normalized ratio do not correlate with bleeding events in Indonesian patients of Minangkabau ethnicity with atrial fibrillation. Open Access Maced J Med Sci 8:192\u2013197. https:\/\/doi.org\/10.3889\/OAMJMS.2020.3436","journal-title":"Open Access Maced J Med Sci"},{"issue":"2","key":"3203_CR40","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jpba.2006.03.019","volume":"42","author":"S Sun","year":"2006","unstructured":"Sun S, Wang M, Su L, Li J, Li H, Gu D (2006) Study on warfarin plasma concentration and its correlation with international normalized ratio. J Pharm Biomed Anal 42(2):218\u2013222. https:\/\/doi.org\/10.1016\/j.jpba.2006.03.019","journal-title":"J Pharm Biomed Anal"},{"key":"3203_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.gene.2013.03.128","volume":"523","author":"OD Castel\u00e1n-Mart\u00ednez","year":"2013","unstructured":"Castel\u00e1n-Mart\u00ednez OD, Hoyo-Vadillo C, Sandoval-Garc\u00eda E, Sandoval-Ram\u00edrez L, Gonz\u00e1lez-Ibarra M, Solano-Solano G et al (2013) Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations. Gene 523:167\u2013172. https:\/\/doi.org\/10.1016\/j.gene.2013.03.128","journal-title":"Gene"},{"key":"3203_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.gene.2014.12.068","volume":"558","author":"B Villegas-Torres","year":"2015","unstructured":"Villegas-Torres B, S\u00e1nchez-gir\u00f3n F, Jaramillo-Villafuerte K, Sober\u00f3n X, Gonzalez-covarrubias V (2015) Genotype frequencies of VKORC1 and CYP2C9 in native and mestizo populations from Mexico, potential impact for coumarin dosing. Gene 558:235\u2013240. https:\/\/doi.org\/10.1016\/j.gene.2014.12.068","journal-title":"Gene"},{"key":"3203_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2125.2008.03113.x","volume":"65","author":"UP Kulkarni","year":"2008","unstructured":"Kulkarni UP, Swar BD, Karnad DR, Davis S, Patwardhan AM, Kshirsagar NA et al (2008) A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation. Br J Clin Pharmacol 65:787\u2013790. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03113.x","journal-title":"Br J Clin Pharmacol"},{"key":"3203_CR44","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/BLOOD-2008-09-176859","volume":"113","author":"C Li","year":"2009","unstructured":"Li C, Schwarz UI, Ritchie MD, Roden DM, Michael Stein C, Kurnik D (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925\u20133930. https:\/\/doi.org\/10.1182\/BLOOD-2008-09-176859","journal-title":"Blood"},{"key":"3203_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3329\/fmcj.v13i1.38018","volume":"13","author":"K Md Arif","year":"2018","unstructured":"Md Arif K, Rahman MA (2018) A review of warfarin dosing and monitoring. Faridpur Med Coll J 13:40\u201343. https:\/\/doi.org\/10.3329\/fmcj.v13i1.38018","journal-title":"Faridpur Med Coll J"},{"key":"3203_CR46","doi-asserted-by":"publisher","unstructured":"Vega AJ, Smith C, Matejowsky HG, Thornhill KJ, Borne GE, Mosieri CN et al (2023) Warfarin and Antibiotics: Drug Interactions and Clinical Considerations. Life 2023, Vol 13, Page 1661. ;13:1661. https:\/\/doi.org\/10.3390\/LIFE13081661","DOI":"10.3390\/LIFE13081661"},{"key":"3203_CR47","doi-asserted-by":"publisher","unstructured":"Zuchinali P, Souza GC, Assis MCS, De, Rabelo ER, Rohde LE (2012) Dietary vitamin K intake and stability of anticoagulation with coumarins; evidence derived from a clinical trial. Nutr Hosp 27:1987\u20131992. https:\/\/doi.org\/10.3305\/nh.2012.27.6.6068","DOI":"10.3305\/nh.2012.27.6.6068"},{"key":"3203_CR48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/J.1365-2125.2010.03672.X","volume":"70","author":"Y Lurie","year":"2010","unstructured":"Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H (2010) Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 70:164\u2013170. https:\/\/doi.org\/10.1111\/J.1365-2125.2010.03672.X","journal-title":"Br J Clin Pharmacol"},{"key":"3203_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1024\/0300-9831.76.2.65","volume":"76","author":"R Couris","year":"2006","unstructured":"Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J et al (2006) Dietary vitamin K variability affects international normalized ratio (INR) coagulation indices. Int J Vitam Nutr Res 76:65\u201374. https:\/\/doi.org\/10.1024\/0300-9831.76.2.65","journal-title":"Int J Vitam Nutr Res"},{"key":"3203_CR50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04787.x","author":"T Khan","year":"2004","unstructured":"Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P et al (2004) Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04787.x","journal-title":"Br J Haematol"},{"issue":"01","key":"3203_CR51","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-02-0111","volume":"109","author":"RC Li","year":"2013","unstructured":"Li RC, Finkelman BS, Chen J, Booth SL, Bershaw L, Brensinger C et al (2013) Dietary vitamin K intake and anticoagulation control during the initiation phase of warfarin therapy: a prospective cohort study. Thromb Haemost (01):195. https:\/\/doi.org\/10.1160\/TH13-02-0111","journal-title":"Thromb Haemost"},{"key":"3203_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bcmd.2010.11.005","volume":"46","author":"LH Cavallari","year":"2011","unstructured":"Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MAG (2011) Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis 46:147\u2013150. https:\/\/doi.org\/10.1016\/j.bcmd.2010.11.005","journal-title":"Blood Cells Mol Dis"},{"key":"3203_CR53","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2217\/pgs.09.65","volume":"10","author":"T Sasaki","year":"2009","unstructured":"Sasaki T, Tabuchi H, Higuchi S, Ieiri I (2009) Warfarin-dosing algorithm based on a population pharmacokinetic\/ pharmacodynamic model combined with bayesian forecasting. Pharmacogenomics 10:1257\u20131266. https:\/\/doi.org\/10.2217\/pgs.09.65","journal-title":"Pharmacogenomics"},{"key":"3203_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12911-014-0128-0\/FIGURES\/7","volume":"15","author":"AK Hamberg","year":"2015","unstructured":"Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M (2015) A bayesian decision support tool for efficient dose individualization of warfarin in adults and children. BMC Med Inf Decis Mak 15:1\u20139. https:\/\/doi.org\/10.1186\/S12911-014-0128-0\/FIGURES\/7","journal-title":"BMC Med Inf Decis Mak"},{"key":"3203_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/07315724.2000.10718081","volume":"19","author":"RR Couris","year":"2000","unstructured":"Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT (2000) Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr 19:801\u2013807. https:\/\/doi.org\/10.1080\/07315724.2000.10718081","journal-title":"J Am Coll Nutr"},{"key":"3203_CR56","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G (2012) Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141:e44S\u2013e88S. https:\/\/doi.org\/10.1378\/chest.11-2292","journal-title":"Chest"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03203-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03203-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03203-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:41:55Z","timestamp":1780926115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03203-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3203"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03203-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no relevant financial or non-financial interests to disclose in relation to the content of this manuscript. Specifically, no personal, professional, or institutional relationships have influenced the work reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was approved by the State Committee on Ethics in Health Research, register number SLP\/09-2021.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standards"}}]}}